Iron deficiency anemia (IDA) continues to be very commonworldwide. Intravenous (IV) iron is an infrequently usedtherapeutic option in children with IDA despite numerousstudies in adults and several small but notable pediatricstudies showing efficacy and safety. Presently, theavailability of newer IV iron products allows for replacementof the total iron deficit at a single setting. These productsappear safer compared to the high molecular weight irondextrans of the past. Herein, we review the medical literatureabout Ferric carboxymaltose (ferinject, Injectafer) that is anintravenous iron preparation for the treatment of irondeficiency in various populations with IDA like patients withchronic disease such us heart failure chronic, kidneydisease, inflammatory bowel disease.